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SELECTED ABBREVIATIONS 
In order of appearance 
 
CNS: Central nervous system AC II: low grade astrocytoma 
AHNSCs: Adult human neural stem cells GBM: Glioblastoma Multiforme 
TSCs: Tumour stem cells VEGF: Vascular derived endothelial 
growth factor 
SVZ: Subventricular zone EGFR: Epidermal growth factor receptor 
SGZ: Subgranular zone PDGFR: Platelet derived growth factor 
Receptor 
ECM: Extra cellular matrix ABCG: ATP-binding cassette transporter 
protein, subfamily G 
GFAP: Glial fibrillary acidic protein Sox2: Sex determining region Y-box 2 
PSA–NCAM: Polysialylated neural cell 
adhesion molecule 
MAP-2: Microtubule-associated protein 2 
EGF: Epidermal growth factor DCX: Doublecortin 
bFGF: Basic fibroblast growth factor O4: Anti-oligodendrocyte marker 
TGF: Transforming growth factor-alpha CNPase: 2`, 3`-cyclic nucleotide 3-
phosphodiesterase 
Shh: Sonic hedgehog qPCR: Quantitative polymerase chain 
reaction 
LIF: Leukemia inhibitory factor FACS: Fluorescence-activated cell sorting 
Wnt: Wingless SCID: Severe immunocompromised 
immunodeficient 
BDNF: Brain-derived neurotrophic factor FTNPs: Filum terminale neural progenitors 
DNA: Deoxyribonucleic acid iPS: Induced pluripotent stem cells 
eGFP: Enhanced Green fluorescent protein  
 
INTRODUCTION
Stem Cells 
Stem cells were first isolated from embryos in the early 80s (1, 2). A decade later, they 
were isolated from the adult central nervous system (CNS) of mice (3) and humans (4-8). 
Based on origin, stem cells can be classified as embryonic, foetal or adult (Fig. 1). Stem 
cells can also be classified based on their ability to generate daughter cells i.e. pluripotent 
(cells that can give rise to all the cell types of the human body e.g. embryonic stem cells) 
(9, 10), or multipotent cells (cells with a more restricted potential, giving rise to progeny 
characteristic of a particular organ system e.g. haematopoietic stem cells) (11-13). 
 
Though the hallmarks of stem cells are contentious, the prevailing view is that bona fide 
stem cells are capable of (1) self-renewal, with an unlimited ability to produce progeny 
indistinguishable from themselves (14), (2) proliferation and (3) multipotent 
differentiation, dividing asymmetrically to generate all the cell types of the tissue from 
which they are derived (15, 16). By applying the aforementioned criteria to cells 
harvested from the adult CNS, stem cells have been prospectively isolated from the 
striatum (3), lateral wall of the lateral ventricles and the spinal cord of rodents (17). In 
adult humans, stem cells have been isolated from the ventricular wall and hippocampal 
zone (4, 7, 8, 18), and are called adult human neural stem cells (AHNSCs). Similar neural 
stem cells have been isolated from other mammalian CNS regions including cortex (5, 
19), substantia nigra (20), white matter (6) and spinal cord (21, 22).  
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 Figure 1. Classification of Stem Cells
Recently, stem cells have also been isolated from solid tumours, including brain tumours 
(23-25). These cells are called tumour stem cells (TSCs) and are similar to AHNSCs. The 
operational definition of a TSC is the ability to self-renew, proliferate and divide 
asymmetrically giving rise to progeny with the varied morphological features, cell 
specific antigens and functional properties characteristic for the tumour (23, 25-28). 
Implicit in this definition, TSCs can recapitulate the parent tumour upon transplantation 
(27, 29, 30).  
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The emerging hypothesis is that TSCs from brain tumours may be derived from neural 
stem cells in the subventricular zone (SVZ) (29, 31). This intimate association between 
the two populations underscores the importance of studying the two populations.   
 
Identity of the Adult Mammalian Neural Stem Cell 
The prevailing view regarding the identity of the adult mammalian neural stem cell is that 
either (1) astrocytes, including radial glia (32, 33) or (2) multi-ciliated ependymal cells 
(17, 34) are the putative resident neural stem cells. Presently, there are two centres in the 
adult human CNS that generate new neurons; the subgranular zone (SGZ) of the dentate 
gyrus of the adult hippocampus and the SVZ (35, 36). In the SVZ, there are three 
different cell types; the migrating neuroblasts (type A cells), the slowly proliferating SVZ 
astrocytes (type B cells) and the clusters of rapidly dividing immature precursors (type C 
cells) (32). Based on elegant experiments using pulse labelling with 3H-thymidine it was 
shown that type B cells are the resident neural stem cells (37); Type B cells incorporated 
3H-thymidine (labels proliferating cells) and gave rise to both type C and A cells (Fig. 2). 
Type B cells are identified as SVZ astrocytes (38) based on their antigenic marker 
expression and ultrastructural characteristics, namely bundles of intermediate filaments, 
gap junctions and multiple processes (32, 39). 
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 Figure 2. The SVZ niche, cell types and stem cell lineage. (a) Frontal schematic of the 
adult mouse brain showing the location of the SVZ in orange between the lateral ventricle 
(LV) and the striatum. The corpus callosum is depicted in dark grey. The box in (a) is 
expanded in (b) and it shows blood vessels (BV) are a likely source of signals for adult 
neurogenesis. A specialized basal lamina (BL) extends from blood vessels into the SVZ 
and terminates adjacent to the ependymal cells (E). (c) Crosssectional schematic showing 
the cell types and their organization in the SVZ. Multi-ciliated ependymal cells (E, grey) 
line the lateral ventricle; chains of neuroblasts (A, red), SVZ astrocytes (B, blue) and 
rapidly dividing Type C cells (C, green) are shown. An ECM-rich basal lamina (BL, 
black) makes extensive contact with all SVZ cell types and forms an essential part of the 
SVZ stem cell niche. SVZ astrocytes (GFAP+) act as stem cells in this region and divide 
to generate transit-amplifying Type C cells (GFAP–/Dlx2+), which in turn divide to 
generate the neuroblasts (GFAP–Dlx2+PSA–NCAM+) that migrate to the olfactory bulb. 
(Reproduced after permission from Doetsch et al., (40))
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Unlike the SVZ and SGZ, the spinal cord is not known to be a site of de novo neuron 
generation. Yet, a quiescent population of cells, fulfilling stem cell hallmarks, has been 
isolated from the spinal cord and cultured as neurospheres in vitro (22, 41, 42). The 
presumed location of the stem cells is around the central canal (33, 41, 43), where mitotic 
activity has been shown in the ependymal cells (44). Indeed, it has already been 
demonstrated that ependymal cells may represent putative neural stem cells (17, 45). 
Interestingly, the ependyma-lined central canal continues into the tail end of the spinal 
cord also known as filum terminale (46-50). The filum terminale also shows strong 
reactivity for neural cell adhesion molecule (N-CAM) (51), a neural progenitor cell 
marker. Given this, the filum terminale may represent a hitherto unknown source of 
neural stem cells. 
The Stem Cell Niche and it’s Factors 
The stem cell niche is the microenvironment consisting of cells, extracellular substrates 
and vasculature that regulates stem cell maintenance, repair and tissue participation, i.e. 
the function of the niche is to regulate self-renewal and fate of the stem cells (52) (Fig. 
2). The central element in the niche is the capillaries, and stem cells are placed in close 
proximity to it (Fig. 2). The niche also safeguards the stem cells from excessive cell 
production which may lead to cancer (12). The molecular components characterizing the 
neural stem cell niche include epidermal growth factor (EGF) and sonic hedgehog (Shh). 
Indeed, in the SVZ infusion of EGF or bFGF increases cell proliferation (53), whereas 
knocking out transforming growth factor-alpha (TGF ), a ligand for the EGF receptor, 
leads to a significant decrease in cell proliferation (54). This suggests that members of the 
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FGF and EGF growth factor families may play an important role in the maintenance of 
adult neural stem cells (55). Recently, Shh was shown to promote proliferation of adult 
neural stem cells both in vitro and in vivo (56-59). Several other signalling pathways are 
also involved in proliferation and differentiation, including LIF (60-62), Wnt (63, 64), 
Notch (65-67) and BDNF (68, 69). Understanding the factors that regulate neural stem 
cells and their niche will help lead to insights into brain repair and maybe even the origin 
of pathological processes e.g. cancer. 
 
Neurogenesis
Neurogenesis is defined as the ability to produce new neurons from stem cells. Evidence 
for this is unambiguous for non-mammalian vertebrates; examples include, (1) 
regeneration of the medial cerebral cortex (which resembles the mammalian hippocampal 
dentate gyrus) in lizards in response to injury (70) and (2) regeneration of newts’ tails, 
limbs, jaws, and ocular tissues including neurons of these regions (71). In mammals, 
however, evidence for neurogenesis was ambiguous (72). In fact, in 1913 Ramon y Cajal 
stated “in the adult centres, nerve paths are something fixed, ended and immutable. 
Everything may die, nothing may be regenerated” (73).  
 
It was in 1961 that adult mammalian neurogenesis was first reported in rodents by Smart 
et al., (74). Later, Altman et al., combined light microscopy with thymidine labelling 
(used to mark cells that are synthesizing DNA in preparation for division), and reported 
ongoing neurogenesis (75) in the hippocampus (76), neocortex (77) and olfactory bulb 
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(78) of rodents. These results were corroborated by Kaplan et al., in the 1980s (79, 80). 
Rakic, however, did not find any such evidence for neurogenesis in the adult brain (81).  
New momentum in the field of neurogenesis came with advances that allowed 
identification of specific cell types by immunocytochemical methods. Using such 
techniques, Nottebohm and his colleagues demonstrated adult neurogenesis in the lining 
of ventricles of songbirds (82, 83). Evidence for adult neurogenesis in the hippocampus 
of the tree shrew, marmoset and macaque (84-87) followed. The most convincing 
evidence, however, was provided using combined retroviral-based lineage tracing and 
electrophysiological studies (88, 89). These studies showed that the newly generated 
neurons were functional i.e. they fired action potentials and exhibited well developed 
voltage-gated sodium and potassium channels. In addition, the neurons exhibited 
functional synaptic contacts; the first synapses were GABAergic and these were followed 
weeks later by glutamatergic synapses (90-92). Such evidence regarding the functional 
phenotype of new neurons was restricted to neural stem cells isolated from rodents. 
 
The first report of neurogenesis in humans was demonstrated by Eriksson and colleagues 
(93). They examined brains of cancer patients who had received BrdU (used to label 
proliferating cells in tumours). Combining BrdU labelling with neuron-specific markers, 
Eriksson et al., demonstrated that new neurons (positive for BrdU and neuronal marker 
NeuN) were generated from dividing progenitor cells in the dentate gyrus. Recently, this 
group has also demonstrated robust neurogenesis in the olfactory bulb of humans, 
comparable in magnitude to that of rodents (94). The above findings of neurogenesis in 
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humans are supported by in vivo brain imaging studies by Manganas et al., (95), who 
have demonstrated the presence of AHNSCs in the human hippocampus using magnetic 
resonance imaging.  
 
Following the initial report of neurogenesis in humans (93), several groups have isolated 
and cultured AHNSCs in vitro (4-8, 18, 96, 97). However, the ability of AHNSCs to 
differentiate into mature, functional neurons capable of firing action potentials and 
synaptic communication (98) has not been tested.  
 
Implications of Neurogenesis 
After the initial discovery of neurogenesis in the postnatal rat hippocampus, several 
studies linked adult-generated neurons in the rodent hippocampus to learning and 
memory (99-101). Van Praag and colleagues showed that mice that run several 
kilometers daily showed a significantly higher percentage of BrdU-positive cells that co-
labelled for the neuronal marker NeuN in the dentate gyrus of the hippocampus (102), 
demonstrating that exercise increases cell proliferation and neuronal differentiation in the 
hippocampus of adult mice. In fact, it has been shown that exercise facilitates recovery 
from brain injury such as stroke (103) and enhances cognitive function in patients (104, 
105). At the cellular level, the newly generated neurons have a striking ability to migrate, 
integrate (106) and extend axons and dendrites in an environment which is largely 
inhibitory for mature neurons (107). This may be due to the exclusively depolarizing 
GABAergic synaptic input (108) the early neurons receive, akin to early neuronal 
development (109, 110). 
 15
Aberrant neurogenesis in the hippocampus is postulated to be linked to the 
pathophysiology of a variety of CNS-related diseases including mood disorders e.g. 
depression. As the major pharmacological and non-pharmacological treatments for 
depression increase hippocampal neurogenesis, it is proposed that antidepressant 
treatments may exert their therapeutic effects by reversing or blocking the reduced 
hippocampal neurogenesis (111, 112). Similarly, impaired hippocampal neurogenesis has 
also been implicated in rodent models of Alzheimer's disease (113, 114). Whether this is 
true in humans is not clear, though it has been shown that factors that positively affect 
hippocampal neurogenesis, including stimulating activities such as reading books and 
playing games, such as crosswords, may reduce the risk of Alzheimer's disease (115).  
 
Aberrant neurogenesis is also seen in patients with seizures. It has been shown that 
seizures increase hippocampal neurogenesis in children under the age of 4 years (116). 
This suggests that seizure-induced neurogenesis in children may contribute to aberrant 
network integration and seizure progression (116). In contrast, older patients with chronic 
seizures do not show similar increases in neurogenesis (117). This may reflect either a 
depletion or exhaustion of the precursor cell pool (116), a phenomenon seen with 
increasing age (53, 118). Imaging studies using magnetic spectroscopy have for the first 
time confirmed the above-mentioned phenomenon, namely that in humans neurogenesis 
decreases with age (95). Such imaging techniques may be used to monitor neurogenesis 
in humans in a wide range of neuro-psychiatric disorders. Also, the efficiency of 
therapeutic interventions may be assessed.  
 16
Stem Cell Therapy 
The aim of stem cell therapy is to treat neurodegenerative diseases including Parkinson’s 
disease. The clinical usefulness of neural stem cells will be determined by their ability to 
provide patients suffering from neurological disorders with safe, long-lasting and 
substantial improvements to their quality of life. Neural stem cells may improve and 
restore function by differentiating and integrating appropriately into regions where 
neurological function is lost. Alternatively, they may exert a neuroprotective effect by 
releasing neurotransmitters or neurotrophic factors that could improve function by 
supporting the survival or regeneration of the existing neurons (119-121).  
 
Understanding the cellular and molecular cues exerted by the microenvironment over 
stem cell differentiation in the adult CNS is important. Transplanting stem cells into 
neurogenic regions (regions that produce or recruit new neurons under normal 
conditions) results in differentiation in a region-specific manner (122, 123); for instance, 
SVZ precursors generate hippocampal neurons when transplanted into the hippocampus 
(124), and SGZ precursors generate olfactory interneurons when transplanted into the 
rostral migratory stream (122). Similarly, multipotent neural precursors from the spinal 
cord (22) produce neurons after implantation into the hippocampus (21). In contrast, 
transplantations into the spinal cord, a non-neurogenic region (a region that does not 
produce or recruit new neurons) (125), only generate glia (21). This highlights the 
significance of the milieu as well as the transplanted cells in determining the outcome of 
transplantations.  
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The traditional concept of stem cell therapy involves isolation of stem cells, propagation 
in vitro and subsequent re-injection into the patient. Human embryonic and foetal stem 
cell use is restricted due to political and ethical controversies. Moreover, large amounts 
of human foetal tissue are needed for therapeutic effects (two to five aborted foetuses per 
side per Parkinson’s patient) (126) and clinical benefit is equivocal (127, 128). An 
alternative is to use immortalized cells. However, as many of these are transformed using 
oncogenes, tumour formation upon transplantation is a genuine risk. Consequently, 
AHNSCs present an attractive alternative to the aforementioned sources; they can be 
obtained from the patient herself, either from ventricular wall biopsies obtained 
endoscopically (129) or from temporal lobe surgeries due to refractory epilepsy (4, 18). 
Recently, it was shown that AHNSCs may also be isolated from the olfactory mucosa 
(130). The AHNSCs can then be propagated in vitro to sufficient numbers and 
subsequently transplanted autologously into the patient (96). To achieve clinical effect in 
Parkinson's disease, it is estimated that approximately 80,000 cells are needed (131). As 
the total number of AHNSCs that can be produced from one biopsy is far beyond this 
number (18, 96, 129), it seems likely that sufficient AHNSCs for treating 
neurodegenerative diseases may be obtained by in vitro propagation.  
 
Attracting endogenous neural stem cells and precursor cells to the site of injury may 
represent an appealing alternative to the above-mentioned transplantation paradigm 
(132), as it bypasses in vitro cell propagation and the complications associated with it. 
However, the effect of endogenous precursors in brain repair is extremely limited (133). 
This probably reflects a limited number of neural stem cells or an unfavourable 
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microenvironment (133). Several factors can increase recruitment of endogenous stem 
cells to the site of injury including, neurotrophins BDNF (134) and stromal cell-derived 
factor-1 (SDF-1) (134, 135). More research, however, is needed before such therapy 
becomes clinically available.  
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Recently, stem cells have also been shown to play an important role in brain tumours (28, 
31). These so called TSCs, have been shown to be brain tumour-initiating cells (23, 25, 
26, 136) and are similar to neural stem cells. If TSCs are crucial for tumour initiation and 
propagation, then treatments designed to target them could prove highly effective. Thus, 
given the intimate association between neural stem cells and TSCs, the second part of my 
thesis describes brain tumours and the role TSCs play in such tumours. 
 
Hallmarks of Cancer 
There are several hallmarks that characterize the cells that develop cancer. Cancer cells 
disregard internal and external growth-inhibition signals and display unlimited mitosis; 
they are self-sufficient and have limitless replicative potential; they bypass mechanisms 
that detect mutation and apoptosis, allowing accumulation of mutations and genetic 
instability; angiogenesis and the ability to invade surrounding normal tissue as well as to 
metastasize to distant sites are also characteristic (137, 138). 
The Stochastic Model of Cancer 
According to the stochastic model of cancer, any somatic cell can give rise to tumours 
when exposed to the right conditions, though the probability of this is very low (30). 
Thus, serial acquisition of genetic alterations in somatic cells (139), results in induction 
of genes promoting proliferation, silencing of genes inhibiting proliferation and 
bypassing of genes involved in programmed cell death. Based on this model, glioma 
heterogeneity may result from continuing mutations in cells of different phenotypes or 
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from cells being trapped within the tumour matrix. Unfortunately, the model fails to 
adequately explain the origin of some gliomas, such as the mixed oligoastrocytoma. 
Classification of Gliomas 
The term glioma was first coined by Virchow in 1846, and he postulated that the tumours 
arose from glial cells (140). Then in 1875, Golgi showed that some brain tumours 
contained distinctive star-shaped neuroglial cells (141). The basis of modern-day neuro-
oncology, however, is attributed to Bailey and Cushing who in 1926 wrote the book, A
Classification of the Tumours of the Glioma Group on a Histogenetic Basis with a 
Correlated Study of Prognosis (142). They classified brain tumours based on the 
predominant cell type and its similarity to the normal brain cell type i.e. neuron, astrocyte 
or oligodendrocyte. Thus, the classification of primary brain tumours is based on cellular 
origin as well as histological appearance (143, 144). Hence, astrocytomas, the most 
common type of glioma, are so called as they resemble astrocytes. Further, based on 
grade of differentiation, astrocytomas are divided into four groups; low grade pilocytic 
astrocytomas (Grade I), well differentiated diffuse astrocytomas (AC II), malignant 
anaplastic astrocytomas (Grade III) and high grade glioblastoma multiforme (Grade IV, 
GBM) (145). The hallmark of malignant astrocytic gliomas is invasion into brain tissue 
(146). The classification of tumours predicts malignancy, invasive potential and thereby 
clinical prognosis and choice of therapy; low grade astrocytomas have a better prognosis 
and are more likely to respond to present treatment modalities compared to high grade 
astrocytomas (147).  
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Epidemiology of Gliomas 
Malignant gliomas are the most common primary CNS tumours in adults, accounting for 
78% of all primary malignant CNS tumours (148). The overall incidence of brain 
tumours in Norway has recently been reported to be ranging from 7.2 to 13.8 per 100,000 
person-years (149). These rates are on the rise both in children (150-152) and adults 
(153-155). Whilst the increase in tumour incidence is attributed mainly to improved 
diagnosis (156, 157), including an increasing willingness on the part of the physician to 
pursue a diagnosis for older patients (158), some reports ascribe the change in incidence 
to be a real increase (152, 159). 
 
Treatment Options for Gliomas 
The current standard treatment includes surgical resection, radiation therapy and 
chemotherapy. The role of surgery is two-fold; firstly, it helps in establishing a diagnosis 
(160, 161) and secondly, it allows for the removal of as much tumour tissue as is possible 
while preserving the patients’ neurological functions. Extensive tumour resection leads to 
increased survival (162-164). Regarding low grade gliomas, the role of surgery is 
controversial (165-168), however, a recent study by Sanai et al., suggests that more 
extensive surgical resection is associated with longer life expectancy also for these 
gliomas (162).  
 
Adjuvant postoperative radiation therapy is a standard-of-care for the management of 
high grade gliomas (169). Prospective clinical trials have shown that survival increases 
linearly as radiation dose is increased (170), though the use of such treatment is 
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controversial regarding low grade gliomas (171). Adjuvant chemotherapy is also well 
established in glioma therapy especially for GBMs. Studies have shown a survival benefit 
for patients receiving chemotherapy and radiation therapy when compared with patients 
receiving radiation therapy alone (172, 173). In fact, recently it was shown that when 
chemotherapy with Temozolomide was combined with radiotherapy, it resulted in a 
statistically significant survival benefit for GBM patients with a median survival of 14.6 
months (174). However, not all patients benefited (175). 
 
Despite the aforementioned therapeutic paradigms, the prognosis for GBMs has remained 
unchanged for three decades (147, 148). Given the dismal prognosis of high grade 
astrocytomas, several novel drugs are presently being clinically tested; (1) A humanized 
neutralizing monoclonal antibody Bevacizumab (Avastin; Genentech, South San 
Francisco, Calif) against VEGF, a growth factor needed for new blood vessel formation 
in gliomas (148). Bevacizumab has been shown to have significant anti-tumour effect in a 
phase 2 trial (176, 177). (2) A monoclonal antibody against EGFR cetuximab (Erbitux; 
ImClone Systems, New York, NY) is being clinically evaluated (178) as it has been 
shown to exhibit anti-tumour effect (179). EGFR amplification is seen in around 50 % of 
GBMs (180). (3) A kinase inhibitor of PDGFR imatinib mesylate (Gleevec; Novartis) 
(181) has been shown to be important in high-grade glioma growth and angiogenesis 
(148) is also being tested. 
 
Despite the multi-modal treatment of gliomas available today, clinical recurrence is 
universal and it most often occurs within 2 cm of the resection margin (182). The 
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prognosis for patients with GBM has changed little in the past three decades and survival 
averages ~1 year (147, 148). Our paramount inability to treat this disease may reflect our 
lack of understanding of glioma biology.  
 
Gliomas, the Stem Cell Model and the Tumour Niche 
In contrast to the stochastic model of cancer, where any cell is capable of giving rise to a 
tumour, the stem cell model of cancer, states that cancer can be viewed as an abnormal 
organ (30), derived by a small fraction of cells capable of self-renewal and proliferation 
known as TSCs (30, 183, 184). Based on this model, gliomas are thought to be initiated 
and propagated by TSCs (27). Indeed, TSCs were first isolated from brain tumours by 
Ignatova et al., (24) and similar cells have been isolated from both paediatric GBM (23, 
26) and adult GBM (25). The TSCs can generate a phenocopy of the parent tumour upon 
transplantation in mice and maintain the ability to produce tumours upon serial 
transplantation in mice – a gold standard assay for TSCs (27).  
 
The stem cell hypothesis evolved because of the similarities between normal neural stem 
cells and TSCs, including nestin expression (185-187), cell signalling pathways 
governing self-renewal and proliferation, including Shh (56, 188) and Notch (189-192) 
and cell surface molecules such as CD 133 (23) and A2B5 (193). Microarray studies have 
revealed an overlap between the molecular signatures of GBMs and progenitors from the 
developing forebrain (194). These similarities suggest that TSCs may arise from neural 
stem cells that have acquired mutations making them tumourigenic. Indeed, upon 
transplacental administration of a potent neurocarcinogen N-ethyl-N-nitrosourea (ENU) 
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(195, 196), many gliomas started out in the SVZ, a site harbouring neural stem cells (197, 
198). As the gliomas grew, however, they moved away from the site of initiation and this 
may explain their seeming discontinuity from the SVZ (199). Similarly, deletion of 
tumour suppressor gene p53 in neural stem cells initiates gliomagenesis in the SVZ (200). 
Recently, it was shown that even the origin of medulloblastoma, an aggressive childhood 
brain tumour, could be traced to neural stem cells (201, 202). 
 
Similar to the neural stem cell niche, it has been suggested that TSCs exist in aberrant 
stem cell niches (203) and deregulation of extrinsic factors within the niche might lead to 
uncontrolled proliferation of stem cells and hence tumourigenesis. A hallmark of GBMs 
is the disorganized blood vessel formation (203) and it was recently shown that CD 133+ 
TSCs produced high levels of VEGF which may contribute to tumour initiation (204). 
Indeed, TSCs within GBMs are located in close proximity to tumour capillaries which 
promote the formation and maintenance of TSCs within these vascular niches (205). The 
tumour niche may also protect the TSCs from chemotherapy (206) and radiotherapy 
(207). If this is the case, targeting these microenvironments may prove a highly effective 
treatment of cancer.  
  
Implications of the Stem Cell Model of Gliomas 
Given the similarities between neural stem cells and TSCs, applying the principles of 
stem cell biology to gliomas changes the way we study, diagnose and treat such tumours.  
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Traditionally, treatments have focussed on removing the bulk of the tumour tissue 
surgically and then non-discriminately killing the proliferating cells using radiotherapy 
and chemotherapy. However, this does not translate into clinically significant increases in 
patient survival (147). The lack of effect of chemotherapy may be explained by the high 
levels of ATP-binding cassette transporter protein (ABCG) (208-210) and enhanced 
DNA repair mechanisms (211) that TSCs possess. This highlights that effective treatment 
may depend on differential drug sensitivity assays discriminating TSCs from the tumour 
bulk. Similarly, assays identifying and discriminating TSCs from neural stem cells may 
help in designing new therapies aimed at destroying the former and preserving the latter. 
Given that TSCs are tumour-initiating cells, eradicating TSCs could prove highly 
effective.  
 
Current prognosis of patients with brain tumours depends on tumour characteristics 
(histology, grade of differentiation, extent of resection, etc.) and patient characteristics 
(age, etc.). As apparently identical tumours behave differently, it is difficult to predict 
prognosis. Interestingly, it was recently shown that the putative TSC marker CD 133 may 
predict patient survival and risk for tumour re-growth (212). This suggests that prognostic 
models based on TSC populations may be useful, provided that TSCs are specifically 
being identified and characterized.  
 
Considering that cellular therapies are being developed for neurodegenerative diseases 
and given that activation of stem cell pathways may lead to tumour initiation, one has to 
be cautious before such therapies can be translated into the clinics. In fact, it was shown 
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that even modified embryonic stem cells-generated cells could be potentially 
tumourigenic (213).  
 
The stem cell model of cancer may also help in establishing appropriate rodent cancer 
models which resemble human cancers more closely. Using a stem cell virus, Welm et
al., showed that expression of c-Met and c-Myc in primitive cells produced mammary 
carcinomas (214) similar to those found in humans. Similarly, Kim et al., have developed 
an animal model that targets normal lung stem cells to produce adenocarcinomas that 
resemble those found in human lung cancers (215). Having representative rodent models 
that correctly reflect tumour pathogenesis gives more relevance to the results obtained 
from such models. This is important when new therapeutic paradigms tested in rodent 
models are translated into the clinics. 
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AIMS
 
1. To isolate and propagate putative neural stem cells from adult human ventricular 
wall biopsies and to examine the ability of the cells to develop into functional 
neurons, including their ability to fire action potentials as well as to communicate 
through synapses (98). (Paper I). 
2. After confirming the neurogenic potential of AHNSCs, the next step was to 
characterize the temporal profile of the electrophysiological development of the 
neurons differentiated from AHNSCs. (Paper II).
3. To isolate putative neural stem cells from adult human filum terminale and 
examine the potential of the cells to differentiate into functional neurons in vitro 
and in vivo. (Paper III).
4. To systematically compare putative neural stem cells isolated from ventricular 
wall biopsies to TSCs isolated from low grade and high grade gliomas in vitro and
in vivo. (Paper IV).
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MATERIALS AND METHODS 
In vitro 
Cell Culture 
Ventricular wall biopsies were obtained (1) from patients undergoing surgery due to 
intractable temporal lobe epilepsy (papers I and II) and (2) endoscopically using a 
Channel neuroendoscope (Medtronic PS Medical, Goleta, CA) during routine 
neurosurgical procedures to treat hydrocephalus (paper I). Filum terminale biopsies were 
obtained from patients undergoing surgery for spinal cord pathology (paper III). 
Biopsies from both AC II and GBM were harvested from patients undergoing tumour 
resections (paper IV). Tissue harvesting was approved by the Norwegian National 
Committee for Medical Research Ethics and the Ethical Committee at the Karolinska 
Hospital (Dnr 01-294) and written consent was obtained from each patient. Radiology 
and histopathology was used to confirm diagnosis in the aforementioned patient groups.  
 
The samples were transported from the operating theatre to the lab in Leibowitz-15 
medium (L15) (Invitrogen Corp., Carlsbad, CA) at 4°C. The tissue was mechanically 
dissociated with a scalpel and placed in 500 μl trypsin-ethylenediamine tetra-acetic acid 
(trypsin-EDTA; Sigma, St Louis, MO) and 200 μl deoxyribonuclease (4000 U/ml; 
Sigma) (paper I), papain 13.2 U/ml (Sigma) and deoxyribonuclease (200 U/ml; Sigma) 
(paper II) and trypsin-EDTA (×1; Invitrogen) (papers III and IV). The dissociated 
suspension was passed through a 70 μm strainer (BD Biosciences, San Jose, CA), and 
resuspended as single cells at clonal density in neurosphere medium (216), DMEM/F12 
(Invitrogen) supplemented with B27 (x1; Invitrogen), 10 ng/ml bFGF (R&D Inc, 
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Minneapolis) and 20 ng/ml EGF (R&D Inc). Cells were cultured at 37°C in 6% CO2 and 
20% O2. The cultures were supplemented with 10 ng/ml bFGF and 20 ng/ml EGF twice a 
week, and additional 1 % of the final volume of DMEM/F12 was added once a week. The 
neurospheres were enzymatically dissociated, as referred to earlier, before their centres 
became necrotic, and resuspended in neurosphere medium. The time taken for 
neurospheres to reform and the size of the neurospheres was measured. To ensure strict 
clonal conditions, single cells were manually isolated with a micromanipulator 
(Eppendorf, Westbury, NY) and cultured further. Differentiation of cells from 
neurospheres was induced by adding 2 % foetal calf serum (FCS, PAA Laboratories, 
Pasching, Austria), removal of mitogens and plating on 20 ng/ml poly-L-ornithine-coated 
(Sigma) or 20 ng/ml laminin-coated glass bottom dishes (WillCo Wells BV, Amsterdam, 
The Netherlands) or 4-well glass slides (Nunc, Roskilde, Denmark).   
 
Co-Culture of Neural Stem Cells and Tumour Stem Cells
Spheres resulting from AHNSCs and TSCs were stained using the fluorescent Cell-
Tracker dye 2μM CFDA-SE (carboxy fluorescein diacetate succinimidyl ester - 
excitation 492 nm, emission 517 nm - Molecular Probes, Eugene, OR) or the fluorescent 
lipophilic tracer 0.1% DiI (1,1-Dioctadecyl-3,3,3,3-tetramethylindocarboxcyanine - 
excitation 492 nm, emission 517 nm - Molecular Probes) respectively, according to the 
manufacturer’s protocol. The labelled spheres were washed, centrifuged, and suspended 
in a 1:1 ratio, and followed on a Leica DM 4000 B fluorescence microscope or a Leica 
TCS SP2 confocal microscope (Leica Inc, Kista, Sweden).   
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Immunocytochemistry 
Immunostaining was performed as previously described (17, 216, 217), with the 
following primary antibodies and dilutions (rb: rabbit, ms: mouse, gp: guinea pig, gt: 
goat); stem cell markers, human specific nestin (HuNest, ms, 1:1000; R&D Inc) and 
Sox2 (rb, 1:500; Chemicon, Temecula, CA); neuronal markers, microtubule-associated 
protein 2 (MAP-2, rb, 1:500; Chemicon), doublecortin (DCX, gt, 1:100; Santa Cruz 
Biotechnology, Santa Cruz, CA), -III-tubulin (ms, 1:1000; Sigma) and neuronal 
nuclear marker NeuN (ms, 1:1000; Chemicon); glial markers, GFAP (rb, 1:1000; Dako, 
Carpinteria, CA), O4 (ms, 1:100; Chemicon), 2`, 3`-cyclic nucleotide 3-
phosphodiesterase (CNPase, ms, 1:500; Chemicon) and RIP (ms, 1:1000; Chemicon). 
Neurotransmitters were stained with glutamate receptor-1, 2 and 4 (GluR-1, rb, 1:100; 
GluR-2 and 4, ms, 1:100; Chemicon), vesicular glutamate transporter-1 (VGlut-1, gp, 
1:10,000; Chemicon) and glutamic acid decarboxylase (GAD-65, rb, 1:1000; Chemicon). 
In addition, a proliferation marker Ki-67 (rb, 1:100; Dako), human specific nuclei (HuN, 
ms, 1:200; Chemicon), inflammation/microglial marker OX42 (ms, 1:1600; Harlan 
SERA-LAB, Loughborough, U.K.), synaptophysin (rb, 1:1000; Binding Site, 
Birmingham, England) and laminin (rb, 1:200; Sigma) were used. Either TO-PRO-3 
(1:10 000; Molecular Probes) or Hoechst (1:200; Invitrogen) was used for nuclear 
staining. For secondary antibodies the fluorescent conjugate markers Cy3 (1:1000; 
Jackson, West Grove, PA), Cy5 (1:1000; Jackson), Alexa Fluor 488 (1:500; Molecular 
Probes), Alexa Fluor 594 (1:250; Molecular Probes), fluorescein isothiocyanate (1:150; 
Jackson), or an avidin-biotin complex (ABC-elite, 1:50; Vector, Burlingame, 
CA)/diaminobenzidine (DAB; 50 mg/100 ml, Sigma) were used.  
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Quantitative Polymerase Chain Reaction (qPCR) 
Total RNA was isolated from tissue samples, stem cells and differentiated cells from 
AHNSCs and TSCs using RNAeasy Mini Kit (Qiagen GmbH, Hilden, Germany) and 
subsequently treated with RNase-free DNase I (RQ1 DNase I, Promega GmbH, 
Mannheim, Germany). Reverse transcription and quantitative real time PCR of each 
sample were run in triplicates using the TaqMan PCR Core Reagent Kit and the ABI 
Prism 7900 Sequence Detection System and software (Applied Biosystems, Foster City, 
CA) according to the manufacturer’s instructions. The oligonucleotide primers and 
probes for nestin, -III-tubulin and GFAP were bought from TaqMan Applied 
Biosystems. As an endogenous control, 18S rRNA (TaqMan rRNA control reagents, 
Applied Biosystems) was used. Data acquired were analyzed with the Sequence Detector 
software (version 1.6.3, Applied Biosystems). A standard curve was obtained by 
amplifications of cDNA obtained from serial dilutions of total RNA. Gene expression 
was presented relative to the levels of 18S rRNA.  
Telomeric Repeat Amplification Assay 
Telomerase protein was extracted from AHNSCs and TSCs in CHAPS lysis buffer and 
the activity was detected using PCR-based TRAPeze® XL Telomerase Detection kit 
(Chemicon) according to the manufacturer’s instructions. The assay is based on the test 
samples capacity to add telomeric repeats onto the 3’ end of a substrate oligonucleotide 
(TS). Telomerase activity was measured as TPG/g protein (Total Product Generated/ g 
protein). TPG corresponds to the number of TS primers extended with at least 3 telomeric 
repeats by telomerase in the extract in a 30 minute incubation at 30°C.  
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Retroviral Enhanced Green Fluorescent Protein Transduction 
A moloney murine leukemia based retroviral system was used to generate amphotropic 
replication incompetent viruses. The PhoenixTM amphotropic packaging cell line (218) 
(generously provided by Dr. M. J. T. Veuger, LIIPAT, Institute of Pathology, 
Rikshospitalet, Oslo) was grown in Iscove's Modified Dulbecco's Medium (IMDM, 
Gibco, Pailsy, UK) supplemented with 10% foetal calf serum (PAA Laboratories) and 
antibiotics. Helper-free recombinant retrovirus was produced after transfection with the 
retroviral vector pLZRS-IRES (internal ribosomal entry site)–EGFP (enhanced green 
fluorescent protein) (218) (generously provided by Dr. M. J. T Veuger) into the Phoenix 
cells using a calcium-phosphate transfection kit (Invitrogen). Positive cells were selected 
using 2μg/ml puromycin (Sigma), then grown in IMDM and supernatants containing 
viral particles were collected at 24 hours post-transfection, passed through 0.45 m 
Millex GP filters (Millipore Co., Bedford, MA) and stored at 80 °C.  
 
Untreated T25 tissue culture flasks (BD Biosciences) were coated with 10 g/cm2 rFN 
(Retronectin, Takara Shuzo Co., Shiga, Japan) according to the manufacturer's 
instructions. Retrofibronectin-coated flasks were pre-loaded with retroviral supernatants 
for 4 hrs at 37 °C. The supernatant was then removed, and the plates washed with 
phosphate buffered saline (PBS). Single cell suspensions, AHNSCs or TSCs, were added 
to the virus loaded rFN-coated flasks. The cells were then incubated at 37 °C in an 
atmosphere of 5% CO2 in air for 24-48 hours before the medium was changed to fresh 
complete culture medium. 
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Fluorescence-Activated Cell Sorter Analysis 
For fluorescence-activated cell sorting (FACS), a single-cell suspension of AHNSCs or 
TSCs, was prepared by incubating EGFP+-spheres in trypsin-EDTA at 37°C for 5 
minutes. The EGFP fluorescence was measured using a FACSAria Flow cytometer 
(Becton-Dickinson, San Jose, CA) (219) with a 488 nm argon laser and FL-1 530 nm BP 
emission filter. Highly fluorescent cells were sorted and thereafter transplanted into Fox 
Chase severe combined immunodeficient (SCID, Taconic, Lille Skensved, Denmark). 
 
Electrophysiology
The whole-cell patch-clamp technique was used to examine the neurophysiological 
properties of individual cells. Cells grown in culture dishes were placed in a recording 
chamber on the stage of an inverted microscope (Nikon, Tokyo, Japan). The cultures were 
perfused with DMEM/F12 between 28 and 32°C and bubbled with 95% air and 5% CO2. 
A Multiclamp 700A amplifier and pClamp 8 software (Axon Instruments, Union City, 
CA) was used to control pipette potentials and to inject current during recordings. Patch 
pipettes were pulled from thick-walled borosilicate glass capillaries to resistances of 4–6 
M  and were filled with pipette solution containing (in mM) K-gluconate 125, HEPES 
10, EGTA 10, KCl 5, Mg–ATP 2 and CaCl  0.22  (pH = 7.3) Lucifer Yellow 0.1% 
(Molecular Probes) was added to the pipette solution to retrospectively identify 
immunocytochemical markers of the cells tested with electrophysiology. In addition, all 
cells tested were photographed, and the exact position in the culture dish was marked 
with a thin water resistant pen to facilitate cell identification. Cells tested 
electrophysiologically and those that were positive for the neuronal markers MAP-2 or ß-
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III-tubulin were defined as neuron-like cells and included in analysis. The membrane time 
constant ( in) and input resistance (R ) werein  estimated in current-clamp by the voltage 
responses of the cells to small injected rectangular hyperpolarizing current pulses of –10 
to –30 pA depending on the R  of the cell.in  R  was derived from the linear portion of the 
current-voltage
in
 plot, and in was calculated by minimizing the squared deviation between 
the function and the data between 5 and 25 ms of the pulse. The function used was f(t) = 
V  – [V ·exp(t/ss ss in)], where V  is the steady-state response (220). The voltage-clamp 
protocol for testing active membrane properties
ss
 consisted of a 100 ms hyperpolarizing 
pulse from a holding potential of –70 to –90 mV that preceded each of the depolarizing 
steps to remove inactivation, followed by 200 ms depolarizing steps with 10 mV 
increments at 0.5 Hz, taking the membrane potential from –90 to 60 mV. In the current-
clamp protocol, current pulses (0–0.1 nA, 0.5 Hz) were injected through the patch pipette 
to examine whether the cells were capable of producing action potentials.  
 
During dual patch-clamp recordings, a whole-cell recording was first obtained from one 
cell with morphological and electrical membrane properties characteristic of neuron-like 
development. Subsequently, the second whole-cell recording was made from another 
neighboring and seemingly connected neuron-like cell. The presynaptic cell was recorded 
in current-clamp mode, and a single action potential was evoked by current injection (0.1 
nA). Postsynaptic currents (PSCs) were recorded in voltage-clamp mode. 
 
Spontaneous synaptic events were recorded during single whole-cell patch-clamp 
experiments in voltage-clamp at different holding potentials. GABAergic currents were 
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blocked using 10 μM of bicuculline, while the glutamate-mediated currents were blocked 
by 20 μM of 6-cyano-7-nitroquinoxaline-2, 3-dione (CNQX, blocks AMPA/kainate 
receptors) and 15 μM of D-2-amino-5-phosphonovaleric acid (MK-801, blocks NMDA 
receptors). Solutions were brought from Sigma. Neurons were stimulated with 1 mmol/L 
glutamate from a micropipette positioned close to the cells and the response was blocked 
by glutamate-receptor antagonists 20 μM CNQX and 15 μM of MK-801. The responses 
were recorded using whole-cell voltage-clamp recordings.  
 
Spike threshold was defined as the membrane potential at which the slope of the voltage 
trace increased abruptly during current injection. Spike width was calculated as spike 
duration at 50% of maximum spike amplitude. 
 
Confocal Microscopy 
For confocal imaging an inverted microscope (Nikon) with a confocal imaging system 
(MRC 600, Bio-Rad, Hertfordshire, UK), equipped with an argon ion laser was used. 
Intracellular Ca2+ ([Ca2+]i) was measured using the acetoxymethyl ester of the two Ca2+-
sensitive fluorochromes fluo-3 (fluo-2 AM) and fura red (fura red AM) (221) (Molecular 
Probes). The cells were incubated in DMEM/F12 containing 0.2 μM fluo-3 and 1.8 μM 
fura red for 20 min before the superfluous dye was washed out. Emitted fluorescent light 
was detected using two separate photomultiplier tubes at the wavelengths 525–555 nm 
(fluo-3) and >600 nm (fura red), respectively. Neurons were stimulated by pressure puff 
application of 60 mM of potassium chloride (KCl) for 10 s and one image was acquired 
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every 2 s, and the fluorescence ratio was calculated using the Time Course/Ratiometric 
Software Module (TCSM, Bio-Rad).  
External Test Solutions 
External test solutions included 0.5 μM of tetrodotoxin (TTX) to block voltage-dependent 
sodium channels, 500 μM of nickel chloride (NiCl) to block the voltage-gated Ca2+-
channels, 500 μM of 4-aminopyridine (4-AP) and 5 mM of tetraethylammonium (TEA) to 
block potassium currents. All the solutions were from Sigma.  
 
In vivo 
All animal procedures were approved by the Ethical Committee of Animal Research in 
Northern Stockholm and the National Animal Research Authority in Norway 
 
Transplantation of AHNSCs from Filum Terminale into Adult Rats Exposed to Global 
Ischemia Using a Two-vessel Occlusion Model 
Global ischemia was induced in accordance with a previously published protocol (217, 
222) Adult male Sprague-Dawley rats (270 ± 10 g, Taconic) were anesthetized with 
halothane (Fluothane; AstraZeneca, Södertälje, Sweden), endotracheally intubated, and 
artificially ventilated. The common carotid arteries were exposed bilaterally by means of 
a ventral midline incision and occluded with non-traumatic microvascular clips for 11 
minutes, while keeping the blood pressure below 45 mmHg by increasing the 
concentration of halothane to minimize compensatory flow in the vertebral arteries. 
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Physiological parameters monitored throughout the procedure were rectal temperature 
(37.5 ± 1°C), mean arterial blood pressure, and cerebral blood flow recorded by a laser 
Doppler probe attached to the skull. Control rats did not undergo any surgery. Seven days 
post-injury, rats were anesthetized with an intramuscular injection of Hypnorm (10 
mg/ml fluanisone and 0.2 mg/ml fentanyl; Janssen Pharmaceutica, Beerse, Belgium) and 
Dormicum (1 mg/ml midazolam; Roche, Stockholm, Sweden), and placed in a 
stereotactic frame (David Kopf Instruments, Tujunga, CA, USA). A 2 l cell suspension 
containing 10,000 cells/l was slowly injected, using a cannula (Plastics One, Roanoke, 
VA) attached to a Hamilton syringe (Hamilton Bonaduz, Bonaduz, Switzerland) into 
posterior periventricular region just above the hippocampus (coordinates: anteroposterior, 
-2.8; mediolateral, 2.0; ventrolateral, -2.6 from bregma, with the nose bar set at -2.0. The 
needle was left in situ for 2 min postinjection before being removed slowly. The Sprague-
Dawley rats received immunosuppression with cyclosporine A subcutaneously (4 mg/kg 
every Monday and Wednesday and 8 mg/kg every Friday and the day before 
transplantation) (Sandimmun, Norvartis Sverige AB, Stockholm, Sweden), in accordance 
with a previously published protocol (223). The transplanted rats were lethally 
anesthetized after 10 weeks.    
    
Transplantation of AHNSCs or TSCs into the CNS of Adult SCID Mice 
Fox Chase SCID mice (7 – 9 week old, Taconic) were anesthetized subcutaneously with 
previously described drugs (217), and placed in a stereotactic frame (David Kopf 
Instruments, Tujunga, CA). Immediately prior to transplantation, suspensions of 
AHNSCs or TSCs, native and GFP-tagged, were prepared in L-15 medium, and a 2 l 
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suspension containing 100,000 cells was injected into the right striatum just below the 
corpus callosum using a cannula (Plastics One, Roanoke, VA) attached to a Hamilton 
syringe (Hamilton Bonaduz, Bonaduz, Switzerland). The needle was left in situ for 2 min 
postinjection before being removed slowly. The implanted mice were killed after 14 
weeks or sooner if symptoms including weight loss or poor appetite developed.  
 
Brain and Tissue Processing
The transplanted rodents were killed by deep anaesthesia with Hypnorm/Dormicum and 
transcardial perfusion with 0.9 % NaCl followed by 4 % buffered formaldehyde. The 
fixed brains were cryo-protected in 17% sucrose for 48 hours, cut into 14 μm sections on 
a freezing microtome (Leica), thawed onto Super Frost/Plus slides (Menzel-Gläser, 
Braunschweig, Germany) and stored at -20 C. 
 
Brain sections were stained with (1) haematoxylin and eosin (H & E), (2) 
immunohistochemistry and (3) avidin-biotin complex method. Immunohistochemistry on 
sections was performed as previously described (217, 224). Briefly, sections were 
incubated in primary antibody overnight at 4°C, rinsed 3 times with PBS, incubated in 
secondary antibody at 4°C for an hour, followed by rinsing thrice with PBS. After 
nuclear staining the sections were mounted with PBS/glycerol 1:1.  
 
For avidin-biotin complex staining method, sections were incubated with an avidin block 
solution (Blocking kit, Vector Laboratories, Burlingame, CA) for 1 hour at room 
temperature, followed by washing in PBS. A biotin block solution was added to the 
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primary antibody solution containing HuN and sections were incubated overnight at 4 C. 
The sections were then incubated at room temperature with biotinylated secondary 
antibody (1:200, horse -mouse IgG, Vector Laboratories) for 1 hour and in avidin and 
biotinylated horseradish peroxidase macromolecular complex (Vectastain® Elite® ABC 
kit, Vector Laboratories) for 1 hour, followed by rinses. The signal was visualized using 
diaminobenzidine (DAB, substrate kit for peroxidase, Vector Laboratories). Double-
labeled sections were treated in the same manner with OX42 and the stain was developed 
using the Nova red substrate kit (Vector Laboratories). Slides were air-dried and mounted 
with PBS/glycerol 1:1 (paper III). 
 
Light microscopy slides were analyzed using a Zeiss Axioskop 2 microscope (Zeiss, 
Munich, Germany) and immunolabelled sections were studied using Olympus BX61W1 
FluoView confocal microscope (Olympus, Hamburg, Germany).  
 
Statistics 
The results are presented as mean  S.E.M. Differences were tested with independent-
sample t-tests (Student's t-test), and considered significant when p < 0.05. 
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RESULTS
PAPER I 
In paper I we showed that AHNSCs could be isolated from ventricular wall biopsies 
obtained (1) endoscopically during routine neurosurgical procedures to treat 
hydrocephalus or, (2) during surgery for refractory temporal lobe epilepsy. The AHNSCs 
developed into neurospheres when grown in a defined sphere-promoting medium. They 
were capable of self-renewal and proliferation even after repeated enzymatic dissociation. 
Under differentiating conditions, AHNSCs developed into astrocytes, neurons and 
oligodendrocytes proportionate to their in vivo organization. Importantly, the neurons 
matured over time and developed functional activity. Specifically, after four weeks in 
culture neurons fired low-threshold, overshooting, repetitive action potentials and 
exhibited voltage-gated sodium and potassium ion channels. Furthermore, the neurons 
possessed presynaptic terminals with functional glutamate receptors. Using double patch-
clamp recordings, we showed that functional neurons communicated synaptically when 
integrated in a network.   
PAPER II 
Given that AHNSCs can be propagated as neurospheres in vitro and that they respond to 
differentiation cues developing into mature neurons (paper I), in paper II we 
characterized the stages of electrophysiological development of the neurons differentiated 
from AHNSCs. Early in development, neurons stained only for neuronal markers without 
exhibiting any functional activity. During the second week, ‘depolarizing potassium-
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dependant humps’ followed by calcium-dependant action potentials were seen. Next, 
broad high-threshold sodium-dependant action potentials which gradually developed into 
low-threshold repetitive action potentials by the fourth week were seen. Concomitant to 
electrophysiological maturity, the neurons developed a more polarized and arborized 
appearance with multiple dendrites (Fig. 3). Moreover, after 4 weeks the neurons 
communicated using GABAergic and glutamatergic synapses; post-synaptic currents 
were demonstrated using patch-clamp recordings.  
 
 
Figure 3. (A) Immunocytochemical staining for glial (GFAP, left panel) and neuronal 
(MAP-2, right panel) markers at different stages of development. (B) Whole-cell 
patch-clamp recordings showing responses to a 0.1 nA intracellular current pulse at 
different stages of differentiation. The pulse duration varied from 300 to 500 ms 
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depending on the maturation of membrane properties. Scale bars: 50 μm (A top 
panel); 20 μm (A lower panel); 15 mV and 50 ms (B).
PAPER III 
In paper III using the assays already established in papers I and II, we showed that 
neural progenitors isolated from filum terminale (FTNPs) could self-renew and 
proliferate into neurospheres. This ability to develop into neurospheres was maintained 
even after enzymatic dissociation (passaging). Furthermore, FTNPs exhibited tripotent 
differentiation into neurons, astrocytes and oligodendrocytes. Using patch-clamp 
recordings, we demonstrated that the neurons exhibited low-threshold, overshooting 
action potentials, displaying both the fast inactivating TTX-sensitive sodium current as 
well as 4-AP and TEA sensitive potassium currents. The FTNPs survived transplantation 
into adult CNS exposed to ischemia and no tumour formation was observed. The FTNPs 
were found not only in the graft, but also in the lesioned CA1 region displaying a 
tendency to migrate to areas of pathology. Interestingly, despite neuronal differentiation 
in vitro, FTNPS differentiated only into astrocytes in vivo.  
 
PAPER IV 
In paper IV, we compared AHNSCs isolated from ventricular wall samples to TSCs 
isolated from both AC II and GBM. Though TSCs have been isolated from paediatric low 
grade tumours (23), this is the first report of such cells being isolated from adult AC II. 
Both AHNSCs and TSCs proliferated into spheres, but TSCs showed significantly higher 
growth rate and self-renewal capacity (p < 0.05). This was reflected in their telomerase 
 43
expression which was high in TSCs and correlated to the malignancy grade (GBM>AC 
II) (p < 0.04). AHNSCs, however, had low telomerase expression. To investigate the 
tumour-forming capacity, TSCs and AHNSCs were transplanted into SCID mice. Only 
the TSCs from GBM formed tumours following orthotopic transplantation and the 
tumour-forming ability was retained upon serial transplantations. Upon differentiation in
vitro, (1) TSCs differentiated faster than AHNSCs; (2) There was a dramatic fall in the 
proliferation index (Ki-67) of TSCs (p < 0.05); (3) AHNSCs gave rise to astrocytes, 
oligodendrocytes and neurons, whereas morphologically aberrant bipotent cells often 
expressing both glial and neuronal antigens were seen in TSCs cultures. Whole-cell 
patch-clamp recordings of differentiated progeny uncovered distinct functional 
phenotypes; AHNSCs differentiated into neurons (high electrical membrane resistance, 
ability to generate action potentials) and astrocytes (low membrane resistance, no action 
potentials); in TSCs cultures, only one functional phenotype was seen - cells with high 
electrical resistance and active membrane properties capable of generating action 
potentials. 
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DISCUSSION 
Sources of Neural Stem Cells 
Adult human neural stem cells have been isolated from ventricular wall biopsies from 
patients undergoing surgery for intractable epilepsy (4, 18, 96, 225) or endoscopy due to 
hydrocephalus (129). Other CNS regions including hippocampus (7, 97), cortex (5, 19), 
white matter (6), spinal cord (21, 22) and olfactory bulb/mucosa (130, 226-229) also 
harbour AHNSCs. In fact, a recent report suggested that the CNS may be much more 
neurogenic than previously hypothesized (230). In keeping with this idea of a widely 
neurogenic CNS, we have isolated AHNSCs from a hitherto unknown source, namely 
filum terminale (paper III). Indeed, neural stem cells have been isolated and propagated 
from several non-neurogenic regions including the spinal cord  (22), suggesting that 
similar cells may be isolated from different CNS regions by customizing and optimizing 
isolation and culture protocols (230). Despite similarities between stem cells isolated 
from different regions, there are distinct differences; we show in paper III that despite 
neurogenic differentiation in vitro, FTNPs differentiated into glia in vivo, in contrast to a 
bipotent fate of AHNSCs in vivo (217).  
Non-neural cell types may serve as a source of neural stem cells/neurons e.g. cells from 
the placenta (231), mesenchymal cells (232-234) and adipocytes (231, 235). 
Alternatively, non-neural cells may modulate the local environment to increase neural 
proliferation and maturation of endogenous stem cells (236). It was recently shown that 
human somatic cell types e.g. fibroblasts, could be reprogrammed to undifferentiated 
pluripotent stem cells (237, 238). This is referred to as induced pluripotent stem cells 
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(iPS) (239). Similar reprogramming has been achieved in mice neural stem cells (239). 
Thus, using iPS technology it is possible to generate patient-specific iPS cell lines. 
However, the clinical applicability will depend on optimizing the protocol, eliminating 
the use of retroviral insertional mutagenesis and avoiding teratoma formation (239). 
Though the possibility of obtaining neurons from such sources is attractive, the ability of 
these cells to differentiate into functional neurons that communicate synaptically and 
integrate into a network has to be investigated before they can be considered as tools for 
regenerative therapy. 
Are Neural Stem Cells Isolated from Ventricular Wall Biopsies Obtained During 
Epilepsy Surgery Normal? 
Neural stem cells are usually obtained from ventricular wall biopsies from patients 
undergoing surgery for refractory temporal lobe epilepsy (4, 18, 96). Though epilepsy is 
shown to increase neurogenesis (240, 241), some reports suggest seizure activity to result 
from aberrant neurogenesis (242, 243), bringing into question the normality of the 
isolated AHNSCs. Interestingly, increased hippocampal neurogenesis has been shown in 
patients under the age of 4 years (116) and not in older patients (117). In our study the 
ventricular wall samples were obtained from patients that belonged to the latter group. 
Also, the karyotypic analysis of AHNSCs revealed no gross cytogenetic irregularities 
(18). 
 
In papers I, II and III we showed that differentiated AHNSCs exhibited two functional 
phenotypes; neurons with a high electrical membrane resistance with the ability to 
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generate action potentials and astrocytes with a low membrane resistance unable to 
generate action potentials, in keeping with the normal CNS. Moreover, transplanting 
AHNSCs into adult CNS resulted in differentiation into neurons and glia with no seizure 
activity seen in the recipient rodents (18, 217). Though the evidence presented here is in 
favour of AHNSCs isolated during epilepsy surgery as being normal, more research is 
needed to answer the question definitively.  
 
Bona Fide Neural Stem Cells or Neural Progenitors 
Adult human neurogenesis in vivo was first demonstrated by Eriksson and colleagues 
(93). Adult human neural stem cells were first isolated by Steindler et al., (4). Thus, by 
applying already established assays to AHNSCs from ventricular wall biopsies (papers I 
and II) and filum terminale biopsies (paper III), we showed that AHNSCs could 
proliferate and self-renew into neurospheres. Per definition, a bona fide stem cell is said 
to exhibit extended self-renewal i.e. more than five passages (14). In our hands, the cells 
displayed limited passage number, i.e. they exhibited limited self-renewal. Similar 
limited proliferation and self-renewal has been demonstrated by others (5, 6, 244), 
suggesting that AHNSCs are transitional cells with a limited self-renewal capacity. 
 
Given that the CNS may be more neurogenic than postulated previously (230) and reports 
showing that AHNSCs can be propagated and expanded in vitro for prolonged periods 
(18, 96), suggests that culture paradigms may have to be modified to realize the full 
potential of AHNSCs in vitro. For instance, addition of Shh, a growth factor lacking in 
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our culture conditions, has been shown to increase proliferation and self-renewal of adult 
neural stem cells in rodents (56-59). 
Though it would be advantageous to expand AHNSCs indefinitely and create cell banks, 
it has been shown that after prolonged culture in vitro, stem cells tend to prefer a 
gliogenic fate rather than a neurogenic one (245, 246). Furthermore, long-term cultures 
can per se increase the appearance of mutations and karyotypic changes (247, 248) and 
with it the concern for tumour formation. Given the aforementioned caveats, optimizing 
culture protocols as well as characterization of neural stem cells, over multiple passages 
with respect to tumour initiating ability, has to be documented before such cells can be 
used as therapeutic tools for neurodegenerative diseases. 
 
Significance of Electrically Active Neurons from Neural Stem Cells 
As mentioned earlier, AHNSCs have been isolated and propagated in vitro by several 
groups (4, 7, 96, 249). However, identification of the differentiated progeny has been 
confirmed using antigenic markers. Evidence regarding the functional status of neurons is 
available primarily for rodent neural stem cells (250). As shown in papers I and II 
despite neurons staining for neuronal specific antigens they do not necessarily exhibit 
typical neuronal activity. This underscores the need to test neurons for their functional 
phenotype. Both Nunes et al., (6) and Walton et al., (18) have demonstrated that 
AHNSCs exhibit single broad action potentials. Unfortunately, as such activity has also 
been demonstrated in developing glial cells (251), it is not conclusive evidence for the 
presence of mature functional neurons. In papers I and II, we show that AHNSCs 
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differentiate into cells possessing the hallmarks of neurons, including the ability to 
generate action potentials and communicate via synapses (98).  
 
The functional significance of voltage-gated ion channels underlying the electrical 
activity expressed by the differentiated progeny of the AHNSCs is manifold. Whilst 
potassium channels limit excitability of mature neurons, in immature cells it is 
responsible for migration (252). Calcium channels on the other hand, are important for 
neurite growth, axonal growth and path finding, as well as cell signalling and synaptic 
transmission (253, 254). While sodium channels are important in generating action 
potentials, their overactivity has been associated with epilepsy (255). Knowing that the 
clinical application of neural stem cells will be limited by their ability to develop into 
functional neurons, research optimizing the functional characteristics of neural stem cells 
is necessary.   
 
Using confocal microscopy, we showed that AHNSCs differentiated primarily into 
glutamatergic and GABAergic neurons. Both GABA and glutamate have important 
functions during development, including regulating proliferation and migration, synaptic 
integration and neuronal differentiation (256). Though not specifically tested in papers I,
II or III, AHNSCs are presently being investigated for their ability to generate other 
neuronal phenotypes, including dopaminergic neurons. Were this to be the case, it would 
be possible to transplant cells autologously into patients suffering from 
neurodegenerative diseases, including Parkinson’s disease. This would open a new 
avenue for the treatment of such diseases. 
 49
The Relationship Between Neural Stem Cells and Tumour Stem Cells
It has already been shown that neural stem cells and TSCs share several similarities (28, 
183), including surface expression of CD 133 (23, 34). This may be a consequence of the 
transformation of neural stem cells into TSCs. In fact, neural stem cells are considered 
the most likely candidates for such a transformation due to their long life span and 
increased propensity to accumulate mutations (28).  
 
Though several studies have alluded to an intimate association between neural stem cells 
and TSCs, studies have not compared these two populations. When conducting such a 
comparative study, it is important to look at cells isolated from fresh biopsies and not rely 
on cell lines as shown by Lee et al., (257). Several clinical correlates can be drawn from 
the results of paper IV; (1) The role of TSCs has been shown for GBMs but not for AC 
II in adults (23-26). Thus, identification of TSCs from AC II may present a new 
promising therapeutic alternative for these tumours, given that the role of surgery is 
controversial (165-168); (2) Spheres cultured from TSCs mirror several biological 
features of human brain tumours (258, 259) including growth rate. Such sphere assays 
can thus be regarded a representative model for glioma growth in vitro (259, 260). It can 
be used to study the kinetics of normal and tumour cell movement, as well as tumour 
progression (261-263) and therapy outcome (264, 265); (3) When exposed to 
differentiating conditions, there was a dramatic attenuation in the proliferation of TSCs. 
This suggests that TSCs which escape surgical resection and chemotherapy, would be 
unable to proliferate and thus incapable of giving rise to relapses were they to be 
subjected to differentiation therapy (25). 
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Significance of Voltage-Gated Ion Channels in Tumour Cells 
The presence of functional activity and voltage-gated ion channels has been shown in cell 
lines (266) as well as tumour tissue (267). Paper IV presents the first report of functional 
activity in differentiated progeny of TSCs derived from AC II and GBM. Voltage-gated 
ion channels influence several biological functions including, proliferation and metastasis 
of tumours; it is also well known that potassium channels inhibit apoptosis; in fact they 
may even enhance multidrug resistance in tumour cells (268, 269); indeed, sodium 
channels have been shown to be important for tumour invasiveness (270, 271). Moreover, 
the presence of seizures in patients with brain tumours (272) may be due to the action 
potential generating progeny of the differentiated TSCs. Given the manifold significance 
of voltage-gated ion channels, several channel blockers are being currently tested for 
their anti-tumour activity.  
Neurosurgeons, the Friendly Neighbour 
The studies conducted in this thesis were only possible due to a close collaboration 
between the neurosurgical departments and the research lab. This highlights the 
neurosurgeon’s role as a provider of both normal and tumour tissue from which stem 
cells can be isolated. Equally important, it is the neurosurgeons who will ultimately 
translate bench work to the bedside by offering patients the latest treatments, which often 
stem from basic research.   
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CONCLUSIONS 
The studies in this thesis have looked at neural stem cells isolated from adult human CNS 
and brain tumours. Specifically, AHNSCs were isolated from the ventricular wall and 
filum terminale, while TSCs were isolated from AC II and GBM.   
 
Adult human neural stem cells can be isolated from the ventricular wall, propagated as 
neurospheres in vitro and serially passaged. Upon differentiation, AHNSCs exhibit 
tripotent differentiation into neurons, astrocytes and oligodendrocytes. In fact, AHNSCs 
can respond to differentiation cues and develop into neurons capable of generating 
overshooting, repetitive action potentials and communicating synaptically using 
functional glutamatergic and GABAergic receptors, fulfilling the hallmarks of a neuron 
(98). In fact, cells capable of self-renewal, proliferation and multipotent differentiation 
can also be isolated from hitherto unknown sources, namely filum terminale. This 
supports the emerging hypothesis that the CNS may be more neurogenic than previously 
postulated (230). Despite the similarities between AHNSCs and FTNPs, there are distinct 
differences between the stem cells isolated from the aforementioned sources, e.g. while 
the former adopts a neurogenic fate in vivo, the latter adopts a gliogenic fate. Our results 
highlight the putative neurogenic potential of regions such as filum terminale. Given that 
neural stem cells are potentially invaluable as tools for regenerative therapy, further 
research looking into long-term maintenance and manipulation of in vivo fate need to be 
addressed before clinical applications can be assessed.  
 
 52
Neural stem cells and TSCs share several properties, including self-renewal and 
proliferation (183). Given that TSCs can be isolated from low grade and high grade 
astrocytomas opens numerous therapeutic alternatives for the treatment of such tumours 
by targeting TSCs. Notwithstanding the similarities, TSCs exhibit several key differences 
when compared to AHNSCs including increased rate of self-renewal, proliferation as 
well as generation of morphologically aberrant tumour cells in vitro and upon 
transplantation. Taken together, this suggests that by conducting comparative studies one 
may not only elucidate the stem cell hypothesis, but identify and target TSCs while 
preserving AHNSCs. 
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FUTURE PROSPECTS  
The battle for the perfect neural stem cell is still on. Research looking at standardizing 
and optimizing culture conditions for AHNSCs has to be intensified. Equally important, 
the presence of other sources of neural stem cells needs to be investigated. The potential 
of AHNSCs to develop into diverse phenotypes including dopaminergic neurons deserves 
attention. Additionally, the influence of the microenvironment on transplanted cells is a 
very exciting field that needs examination. The elucidation of the stem cell niche, both in
vivo and in vitro is a pressing issue in basic research and learning how the niche and 
niche-related factors control stem cell fate and direct differentiation into particular cell 
types may provide new therapies in the near future. Knowledge gained may also help 
understand the aberrant tumour niches. Furthermore, the advent of novel technologies 
such as RNA interference and genomic and proteomic analyses of stem cells and their 
progeny, are tools that will not only help elucidate the biology and function of neural 
stem cells but also realize the true potential of stem cells for therapy. 
 
Based on our studies and those of other groups, it is clear that in order to identify and 
target TSCs whilst preserving AHNSCs, comparative studies between the two 
populations are essential. Subsequently, the identified targets can be used to develop new 
treatments for gliomas. Comparative studies will also help elucidate the cell of origin of 
TSCs. Given that brain tumours are still diagnosed based on histological appearance, the 
stem cell model may herald in an era where diagnosis is based on the molecular signature 
of the TSCs. Indeed, it is possible that patient specific treatments may also be available 
with immunotherapy (using the body’s immune system to find and destroy TSCs e.g. 
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vaccines) (273, 274) and gene therapy (using either suicide genes to destroy TSCs, or 
enhancer genes to cause an immune response against the patient’s own tumour) (275-
277).  
 
Another tantalizing concept is the tumour niche, which includes the tumour vasculature 
(12). The niche has a protective role, harbouring the stem cells. It may also provide 
factors to regulate stem cell proliferation and stem cell fate (278). Thus, TSCs might be 
protected from conventional therapies by factors within this niche. In the future, it is 
highly possible that drugs that disrupt the stem cell niche may provide treatment 
alternatives for brain tumours, specifically GBMs.  
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